• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, Sept. 29 Suven Life Sciences Ltd announced on Monday that it has completed the Phase-I single ascending dose study of SUVN-502 in healthy subjects.

The study was conducted at Basel, Switzerland, under a Clinical Trial Application (CTA) approved by SwissMedic, the regulatory authority of Switzerland for therapeutic products.

SUVN-502 is a brain penetrant and orally active candidate intended for the symptomatic treatment of Alzheimer’s disease and other disorders of memory and cognition such as Parkinson’s and Schizophrenia.

The tolerability of SUVN-502 up to the highest dose administered was very good. No serious adverse events occurred. No clinically significant changes or study medication-related abnormalities were observed with respect to ECGs (electrocardiogram) and laboratory evaluations, a company press release said.

“We believe that SUVN-502 has great potential to become a novel treatment for disorders affecting memory and cognition in Alzheimer’s and other dementia”, said Mr Venkat Jasti, CEO of the company. SUVN-502 is the first NCE (New Chemical Entity) of Suven to enter the clinic from a pipeline of six NCEs.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line